Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer

NCT ID: NCT02142790

Last Updated: 2014-07-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31

Brief Summary

This is a open-label study in patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to 3-weekly regimen.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

paclitaxel liposome injection weekly

paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable

Group Type: EXPERIMENTAL

paclitaxel liposome injection

Intervention Type: DRUG

paclitaxel liposome injection every 3 weeks

paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable

Group Type: EXPERIMENTAL

paclitaxel liposome injection

Intervention Type: DRUG

Interventions

paclitaxel liposome injection

Intervention Type: DRUG

Other Intervention Names

LIPUSU

Eligibility Criteria

Inclusion Criteria

• Female or Male >18 years of age and < 70years of age, If female of childbearing potential, pregnancy test is negative before first dose of study drug and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study
• Stage IV disease
• Measurable disease
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Suitable for the treatment with paclitaxel as single agent regimen (first line or prior first line chemotherapy including adriamycin is allowed, If a taxane was part of the adjuvant regimen, at least one year should have transpired since completion of taxane regimen and if Her2+ patient, Herceptin therapy will be allowed.
• Patient has the following values at Baseline: Absolute neutrophil count ≥ 1.5 x 10^9cells/L; platelets ≥ 100 x 10^9 cells/L; hemoglobin ≥ 10 g/dL. Aspartate transaminase (AST or SGOT), alanine aminotransferase (ALT or SGPT) ≤ 2.5x upper limit of normal range (ULN); total bilirubin ≤ 1.5ULN; creatinine ≤ 1.5 mg/dL.
• Informed consent has been obtained.

Exclusion Criteria

• Parenchymal brain metastases.
• History of other malignancy within the last 3 years
• New York Heart Association (NYHA) Grade 2 or greater congestive heart failure,history of myocardial infarction or unstable angina or new occured angina within 6 months prior to study enrollment.
• Concurrent other anticancer therapy.
• History of serious organic disorders (including active infection or Cardiovascular disease), serious hepatic disease, serious blood coagulation diseases, cachexia
• Sensory neuropathy of > Grade 1 at baseline.
• Patients with prior hypersensitivity to paclitaxel
• Pregnant or nursing women
• enrolled in a different clinical study
• No psychiatric illness and other situations that would limit compliance of study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nanjing Luye Sike Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hunan Cancer Hospital

Changsha, Hunan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Quchang Ouyang, MD

Role: CONTACT

oyqc1969@126.com

Facility Contacts

Quchang Ouyang, MD

Role: primary

oyqc1969@126.com

Other Identifiers

LY-TM-LPS-2014-02

Identifier Type: -

Identifier Source: org_study_id